Tags

Type your tag names separated by a space and hit enter

Men with mild erectile dysfunction benefit from sildenafil treatment.
J Sex Med. 2010 Nov; 7(11):3725-35.JS

Abstract

INTRODUCTION

Sildenafil treatment has not been evaluated in a double-blind, placebo-controlled (DBPC) trial specific to men with mild erectile dysfunction (ED), defined by a 22-25 score on the International Index of Erectile Function-erectile function domain (IIEF-EF).

AIM

To assess sildenafil efficacy in sexually dissatisfied men with mild ED.

MAIN OUTCOME MEASURES

Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), IIEF, Quality of Erection Questionnaire (QEQ), Erection Hardness Score (EHS 4=completely hard/fully rigid), general efficacy questions (GEQs), event log questions (hardness sufficient for penetration, duration sufficient for successful intercourse, ejaculation/orgasm, and second erection within 24 hours), and analog scales (erection firmness, reliability, and maintenance, and general sexual performance).

METHODS

Eight-week DBPC flexible-dose (25, 50, or 100 mg) trial with 6-week, open-label (OL) extension.

RESULTS

One hundred and seventy-six men were randomized (mean±standard deviation: age, 50±12 year; ED duration, 3.5±3.2 year). Most had organic or mixed ED. For sildenafil vs. placebo, 66% vs. 89% titrated to 100 mg and efficacy at DBPC end was better, including the EDITS Index score (least squares mean [standard error], 80.3 [2.3] vs. 62.1 [2.5]; P<0.0001); treatment satisfaction (EDITS Index score >50 in 89% vs. 63%; P=0.0001); no ED (IIEF-EF ≥26 in 58% vs. 39%; P<0.05); GEQs (≥4.9-fold greater odds of improved erections and ability to have sexual intercourse); and EHS 4 (47.2% vs. 25.2% of occasions; P<0.0001). At OL end, 93% of men were satisfied (EDITS Index score>50), 77% had no ED, and ≥89% were GEQ responders; mean scores on IIEF domains, the QEQ, and analog scales were >80% of the maximum; 60% of occasions had EHS 4; and event log responses were positive on >80% of occasions, except for second erections (41.9%). Headache, nasal congestion, and flushing, mostly mild to moderate, were the most common adverse events.

CONCLUSION

Men with mild ED derive substantial benefit from sildenafil treatment.

Authors+Show Affiliations

CHUM-St-Luc Hospital, Montreal, QC, Canada. frbenard@videotron.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20946161

Citation

Bénard, Francois, et al. "Men With Mild Erectile Dysfunction Benefit From Sildenafil Treatment." The Journal of Sexual Medicine, vol. 7, no. 11, 2010, pp. 3725-35.
Bénard F, Carrier S, Lee JC, et al. Men with mild erectile dysfunction benefit from sildenafil treatment. J Sex Med. 2010;7(11):3725-35.
Bénard, F., Carrier, S., Lee, J. C., Talwar, V., & Defoy, I. (2010). Men with mild erectile dysfunction benefit from sildenafil treatment. The Journal of Sexual Medicine, 7(11), 3725-35. https://doi.org/10.1111/j.1743-6109.2010.02015.x
Bénard F, et al. Men With Mild Erectile Dysfunction Benefit From Sildenafil Treatment. J Sex Med. 2010;7(11):3725-35. PubMed PMID: 20946161.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Men with mild erectile dysfunction benefit from sildenafil treatment. AU - Bénard,Francois, AU - Carrier,Serge, AU - Lee,Jay C, AU - Talwar,Varun, AU - Defoy,Isabelle, Y1 - 2010/10/04/ PY - 2010/10/16/entrez PY - 2010/10/16/pubmed PY - 2011/2/25/medline SP - 3725 EP - 35 JF - The journal of sexual medicine JO - J Sex Med VL - 7 IS - 11 N2 - INTRODUCTION: Sildenafil treatment has not been evaluated in a double-blind, placebo-controlled (DBPC) trial specific to men with mild erectile dysfunction (ED), defined by a 22-25 score on the International Index of Erectile Function-erectile function domain (IIEF-EF). AIM: To assess sildenafil efficacy in sexually dissatisfied men with mild ED. MAIN OUTCOME MEASURES: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), IIEF, Quality of Erection Questionnaire (QEQ), Erection Hardness Score (EHS 4=completely hard/fully rigid), general efficacy questions (GEQs), event log questions (hardness sufficient for penetration, duration sufficient for successful intercourse, ejaculation/orgasm, and second erection within 24 hours), and analog scales (erection firmness, reliability, and maintenance, and general sexual performance). METHODS: Eight-week DBPC flexible-dose (25, 50, or 100 mg) trial with 6-week, open-label (OL) extension. RESULTS: One hundred and seventy-six men were randomized (mean±standard deviation: age, 50±12 year; ED duration, 3.5±3.2 year). Most had organic or mixed ED. For sildenafil vs. placebo, 66% vs. 89% titrated to 100 mg and efficacy at DBPC end was better, including the EDITS Index score (least squares mean [standard error], 80.3 [2.3] vs. 62.1 [2.5]; P<0.0001); treatment satisfaction (EDITS Index score >50 in 89% vs. 63%; P=0.0001); no ED (IIEF-EF ≥26 in 58% vs. 39%; P<0.05); GEQs (≥4.9-fold greater odds of improved erections and ability to have sexual intercourse); and EHS 4 (47.2% vs. 25.2% of occasions; P<0.0001). At OL end, 93% of men were satisfied (EDITS Index score>50), 77% had no ED, and ≥89% were GEQ responders; mean scores on IIEF domains, the QEQ, and analog scales were >80% of the maximum; 60% of occasions had EHS 4; and event log responses were positive on >80% of occasions, except for second erections (41.9%). Headache, nasal congestion, and flushing, mostly mild to moderate, were the most common adverse events. CONCLUSION: Men with mild ED derive substantial benefit from sildenafil treatment. SN - 1743-6109 UR - https://www.unboundmedicine.com/medline/citation/20946161/Men_with_mild_erectile_dysfunction_benefit_from_sildenafil_treatment_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1743-6095(15)32746-6 DB - PRIME DP - Unbound Medicine ER -